Goodwin has a prominent role in high-stakes cases in key industry sectors such as life sciences and biotechnology, though it also handles significant matters involving REITS and large technology companies. The firm is also increasingly involved in representing financial institutions and fintech companies. Boston-based Deborah Birnbach leads the securities litigation and SEC enforcement department within the complex litigation practice along with Daniel Roeser and Douglas Flaum in New York, Caroline Bullerjahn in Boston, and San Francisco-based Jonathan Shapiro. Bullerjahn is currently representing Chardan Capital Markets LLC, which served as underwriter for SPAC Trident Acquisition Corp in matters arising from its de-SPAC transaction with Autolotto. Roeser, whose track record includes high-profile mortgage-backed securities cases and some of the largest securities class actions in history, is currently acting for residential mortgage REIT Two Harbors Investment Corp. in a case seeking hundreds of millions of dollars in damages. Clients praise ‘the firm’s commitment to go the extra mile’.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘The team is professional and knowledgeable in all aspects of data privacy law. The team was able to quickly ramp up on our product, understand the technical data flows and draft various documents precisely to the point. What stood out most was the firm’s commitment to go the extra mile to provide all required deliverables in high quality upfront, allowing time to incorporate feedback, in multiple cycles, prior to deadlines. Tasks were completed with remarkable efficiency, saving me time and reducing the stress associated with legal proceedings.'
'The firm’s reputation for excellence was evident from my first interaction with them. ’
‘We worked with Daniel Roeser from the New York office. Daniel is not only highly skilled in the legal field but also compassionate and understanding of the situation to provide tailored care and support. His deep understanding of the law, and relentless pursuit to research all avenues, was apparent in the strategic advice provided, which was always up-to-date with the latest legal precedents.
'During the course of my case, Daniel Roeser was exceptionally responsive to my questions and concerns, often going above and beyond to ensure I felt supported. He always kept me informed and made sure that his team maintained open and frequent communication, ensuring that I was never left in the dark about the progress of the case or the options available at every stage of the case. Daniel consistently provided clear and concise advice at each step, making sure I understood all my options. Daniel's tactical acumen and negotiation skills were particularly impressive. He has strong interpersonal skills and is approachable; and this makes it very easy to work with him without worrying about asking too many questions or clarifications.'
‘Goodwin has engaged practice experts as needed. Each has been completely familiar with our matter and has been immediately effective in advancing our efforts. They have been team and goal oriented and impressive in their focus on our needs. Appropriate practice leaders involved whenever necessary. We openly discuss and employ flexible billing arrangements. Goodwin has devoted all necessary resources is assisting us, but never done so without consultation and agreement.’
‘I have enjoyed a decades long relationship with Goodwin. Their command of securities, banking, tax and general corporate matters is extensive and deep. The litigation effort is headed by Dan Roeser, who has provided brilliant efforts and complete knowledge.’

Key clients

Aldeyra Therapeutics and its officers
BELLUS Health, Inc. and its officers
Caribou Biosciences, Inc.
Cedar Realty Trust, Inc., Cedar Realty Trust Partnership, L.P., Bruce Schanzer, Gregg Gonsalves, Abe Eisenstat, Sabrina Kanner, Darcy Morris, Richard Ross, Sharon Stern, Steven G. Ross (“Cedar”)
Chardan Capital Markets LLC
Citrix Systems, Inc.
Cognizant Technology Solutions Corporation
Fate Therapeutics and its officers and directors
Forge Global Holdings, Inc.
Fulcrum Therapeutics, Inc. and its officers
Goldman Sachs lead syndicates of underwriters in a series of US based securities litigations
MabVax Therapeutics Holdings, Inc.
Prime Trust, LLC
Rocket Companies, Inc. and its officers
Silvergate Capital Corporation
Syndicates of Underwriters of Axogen, Inc. (one led by SVB Securities LLC and including Cantor Fitzgerald & Co. and JMP Securities LLC and the other led by Jefferies LLC and including SVB Securities LLC, William Blair & Company, L.L.C., and JMP Securities LLC)
TuSimple Holdings, Inc.
Yieldstreet Inc.

Work highlights

Representing Citrix in a federal securities class action filed in the Southern District of Florida. The securities fraud class action brings claims against Citrix and certain of its current and former officers under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder on behalf of investors who purchased Citrix common stock between January 22, 2020, and October 6, 2021. The lead plaintiff alleges that, during the Class Period, Citrix, a Software as a Service (“SaaS”) company, made misstatements and omissions related to its efforts to transition its business from traditional, on-premise software to subscription-based, cloud software.
Representing Aldeyra Therapeutics, Inc. and certain of its executives in a class action arising from alleged misstatements and omissions concerning ADX-2191, including the Company’s new drug application submitted to the FDA for ADX-2191 to treat primary vitreoretinal lymphoma.
Representing Cognizant Technology Solutions Corporation in a putative securities class action and three putative shareholder derivative actions. These suits arise out of Cognizant’s September 2016 announcement that it had self-reported to the federal government potentially improper payments made to officials in India in connection with obtaining permits for certain facilities.